Latest Conference Coverage
Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD
July 10th 2022The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]
Understanding the Impact of MiCOAS Qualitative Study: Richard B. Lipton, MD
July 8th 2022The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]
Understanding Individual Risks, Improving Trial Designs for Sleep Disorders in Alzheimer Disease
July 7th 2022Ruth Benca, MD, PhD, a professor and the chair of Psychiatry & Human Behavior at Wake Forest School of Medicine, provided insight on the age- and sex-related differences in sleep disorders, and the needed research on the effects of therapeutics in older populations.
Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MSc
July 7th 2022The pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Learning From Patients With Parkinson Disease: Laxman Bahroo, DO
July 6th 2022The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 1 minute]
Properly Assessing Cognition in Patients With Multiple Sclerosis: John DeLuca, PhD
July 4th 2022The senior vice president for research and training at the Kessler Foundation discussed the assessment of cognitive challenges among patients with multiple sclerosis and planning for treatment options when necessary. [WATCH TIME: 4 minutes]
Improvements in Treating Narcolepsy, Idiopathic Hypersomnia Through Xywav
July 2nd 2022Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.
Regularly Measuring Cognition in MS, and Treating Cognitive Issues: John DeLuca, PhD
July 1st 2022The senior vice president for research and training at the Kessler Foundation spoke about the critical need to prioritize cognitive challenges among patients with multiple sclerosis, as it remains among the chief complaints. [WATCH TIME: 4 minutes]
Benefits From the 2022 ATMRD Congress and Multidisciplinary Teams: Laxman Bahroo, DO
June 30th 2022The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital and presenter at ATMRD offered his insight into the benefits of multispecialty meetings. [WATCH TIME: 3 minutes]
Awareness of Botulinum Toxins in the Movement Disorder Landscape: Laxman Bahroo, DO
June 29th 2022The assistant professor of neurology and codirector of the Neurology Residency Program at MedStar Georgetown University Hospital shared his thoughts on the 2022 ATMRD Congress and the steps forward made in patient awareness of therapeutic options. [WATCH TIME: 3 minutes]
Evobrutinib, BTK Inhibitors, and the Associations With Neurofilament Light: Jens Kuhle, MD, PhD
June 27th 2022The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]
Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH
June 25th 2022The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
June 24th 2022The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]
Fosgonimeton Fails to Reach End Points, but Shows Mechanistic Potential in Alzheimer Disease
June 23rd 2022After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.
The ATMRD Congress and Importance of Accessibility as a Clinician: Jill Farmer, DO, MPH
June 23rd 2022The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]
